查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553413

造血系统恶性市场规模、份额、趋势分析报告：依疾病、治疗、最终用途、地区、细分市场预测，2024-2030年

Hematologic Malignancies Market Size, Share & Trends Analysis Report By Disease (Leukemia, Lymphoma), By Therapy (Chemotherapy, Immunotherapy), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格
简介目录

造血系统恶性市场成长与趋势：

预计2030年全球造血系统恶性市场规模将达1,138.9亿美元，预计2024年至2030年复合年增长率为8.0%。

造血系统恶性盛行率的增加和强大产品平臺的存在预计将推动市场发展。此外，併购的增加预计也将加速成长。

此外，新兴国家政府正在增加医疗保健支出并发展医疗基础设施。这可能会减少患者的自付费用，并被认为是推动造血系统恶性市场的关键因素之一。

最近，已证实政府消息人士正在倡议资助研究机构进行突破性的肿瘤学研究。这是市场的主要成长动力，因为它可以帮助研究机构在不受财务限制的情况下进行更大规模的研究。联邦对肿瘤学研究的资助导致癌症检测、预防、诊断、治疗和患者生活品质方面取得了重大进展。癌症研究的进步使更多的癌症患者得到成功治疗。癌症研究投资的增加预计将在预测期内推动市场成长。

造血系统恶性市场报告亮点

  • 由于强大的重磅产品管道，多发性骨髓瘤预计将成为预测期内成长最快的细分市场之一。
  • 由于可用产品数量众多且患者人数众多，慢性骨髓性白血病被认定为 2016 年最大的白血病亚型。
  • 由于化疗作为一线治疗的偏好和广泛的产品组合，其在 2016 年的治疗方法基础上占据了最大的市场份额。
  • 免疫疗法因其低副作用和高效率而成为发展最快的领域。
  • 由于主要企业的本地化和併购的增加，北美在 2016 年占据了市场主导地位。
  • 由于经济状况改善和医疗保健支出增加，预计亚太地区将成为未来十年成长最快的地区，2017 年至 2025 年复合年增长率良好。
  • 主要参与者包括辉瑞、罗氏、赛诺菲、百时美施贵宝、艾伯维、诺华、GlaxoSmithKline Plc、新基、强生服务，例子包括工业公司。
  • 许多主要企业都专注于扩大产品系列、开发新治疗方法和进行收购。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章造血系统恶性市场的变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 造血系统恶性市场分析工具
    • 波特的分析
    • PESTEL分析

第四章造血系统恶性市场：依疾病分类的预估及趋势分析

  • 细分仪表板
  • 造血系统恶性市场：2023 年及 2030 年疾病特异性变异分析
  • 白血病
  • 淋巴瘤
  • 骨髓瘤

第五章造血系统恶性市场：依治疗方法估算与趋势分析

  • 细分仪表板
  • 造血系统恶性市场：2023 年和 2030 年治疗的变异分析
  • 化疗
  • 免疫疗法
  • 标靶治疗
  • 其他治疗

第六章造血系统恶性市场：依最终用途分类的估算与趋势分析

  • 细分仪表板
  • 造血系统恶性市场：2023 年和 2030 年最终用途的变化分析
  • 医院药房
  • 零售药房
  • 其他的

第七章造血系统恶性市场：区域估计及趋势分析

  • 2023 年及 2030 年造血系统恶性市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Pfizer Inc.
    • F. Hoffmann-LA Roche Ltd
    • Sanofi SA
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
    • Novartis AG
    • GlaxoSmithKline PLC
    • Amgen Inc.
    • Takeda Pharmaceutical Co. Ltd
    • Johnson &Johnson
简介目录
Product Code: GVR-1-68038-687-5

Hematologic Malignancies Market Growth & Trends:

The global hematologic malignancies market size is estimated to reach USD 113.89 billion in 2030 and is projected to grow at a CAGR of 8.0% from 2024 to 2030. Increasing incidence of hematologic malignancies and presence of a strong product pipeline are estimated to boost the market. Moreover, increasing number of mergers and acquisitions are also expected to accelerate growth.

Furthermore, governments of developing countries are spending more on healthcare and on improving healthcare infrastructure. This is likely to reduce out-of-pocket expenditure for patients. which is considered as one of the major factors driving the hematologic malignancies market.

Recently it has been seen that the government sources are taking an initiative in funding the institutes for breakthrough oncology research. This is a major growth driver for the market as it will support the institutes to conduct their research on a larger-scale without any financial constraints. Federal government funding for research in oncology has led to a substantial development in cancer detection, prevention, diagnosis, treatment and quality of life for patients. Due to the advancement in cancer research, more patients with cancer are being successfully treated. The increasing investment in cancer research is expected to boost the growth of market during forecast period

Hematologic Malignancies Market Report Highlights:

  • Multiple myeloma is expected to be one of the fastest growing segments over the forecast period owing to strong pipeline of blockbuster products
  • Chronic myeloid leukemia was identified as the largest leukemia subtype in 2016 due to availability of large number of products and high number of target population
  • Chemotherapy held the largest share in 2016 on the basis of therapy due to its preference as first line of therapy and wide product range
  • Immunotherapy is anticipated to be the fastest growing segment and this can be attributed to lower adverse effects and higher efficiency
  • North America dominated the market in 2016 owing to local presence of key players and increasing number of mergers and acquisitions
  • Asia Pacific is expected to be the fastest growing region over the next decade with lucrative CAGR from 2017 to 2025 due to improving economic conditions and rising healthcare expenditure
  • Some of the key players are Pfizer, Inc.; F. Hoffmann-LA Roche Ltd; Sanofi; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited
  • Most of the key players are focusing on expanding their product portfolios, development of new treatment, and acquisitions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hematologic Malignancies Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Hematologic Malignancies Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Hematologic Malignancies Market: Disease Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Hematologic Malignancies Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Leukemia
    • 4.3.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Lymphoma
    • 4.4.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Myeloma
    • 4.5.1. Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Hematologic Malignancies Market: Therapy Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Hematologic Malignancies Market: Therapy Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Chemotherapy
    • 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Immunotherapy
    • 5.4.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Other Therapies
    • 5.6.1. Other Therapies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Hematologic Malignancies Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Hematologic Malignancies Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other
    • 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Hematologic Malignancies Market: Regional Estimates & Trend Analysis

  • 7.1. Hematologic Malignancies Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Hematologic Malignancies Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Pfizer Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. F. Hoffmann-LA Roche Ltd
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Sanofi SA
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Bristol-Myers Squibb Company
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. AbbVie Inc.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Novartis AG
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. GlaxoSmithKline PLC
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Amgen Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Takeda Pharmaceutical Co. Ltd
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Johnson & Johnson
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives